AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03955029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Interval training
Description: heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session).
Study NCT03955029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Interval training
Description: warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session)
Study NCT00209690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briplatin
Description: 15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02911909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi
Description: Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
Study NCT02911909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Patients will receive standard of care post-operative ACL reconstruction rehabilitation
Study NCT02199977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Free Malaria Rapid Diagnostic Test
Description: Malaria RDT is offered free if patients choose to be tested
Study NCT02199977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conditional ACT voucher
Description: Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug.
Study NCT04401631 — intervention group
Intervention type: DEVICE
Intervention: Blood Collection
Description: Between-Run Reproducibility K3-EDTA venous whole blood 3 mL 1 venous draw~Operator-to-operator imprecision (abioSCOPE) K3-EDTA capillary whole blood 0.05 mL/draw; 0.15 mL total 3 finger sticks (3 different fingers)~Sample type comparison (abioSCOPE) K3-EDTA capillary whole blood, venous serum, venous K3-EDTA plasma 0.35 mL (finger stick), 9 mL of whole blood to get a minimum of 3 mL of serum and 9 mL of whole blood K3-EDTA to get a minimum of 3 mL of plasma 1 finger stick; 1 venous draw into serum tube (9 mL) and 1 venous draw into K3-EDTA plasma tube (9 mL), in total 18 mL~Method comparison (abioSCOPE and ImmunoCAP/Phadia) K3-EDTA capillary whole blood, venous K3-EDTA plasma 0.05 mL (finger stick), 9 mL of whole blood to get a minimum of 3 ml of plasma 1 finger stick; 1 venous draw into K3-EDTA plasma tube (9 mL tube)
Study NCT04444141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: The subjects will receive AK104 till disease progression or for a maximum of 24 months.
Study NCT02598999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-009
Description: Solution for inhalation administered through nebulization
Study NCT02598999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSCN-
Description: Solution for inhalation administered through nebulization
Study NCT02598999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bLF
Description: Solution for inhalation administered through nebulization
Study NCT02598999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
Study NCT00862277 — intervention group
Intervention type: BIOLOGICAL
Intervention: Menactra®
Description: 0.5 mL, Intramuscular (from a previous study)
Study NCT02199977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Malaria Rapid Diagnostic test for a charge
Description: Participants can receive a malaria RDT for a set amount (i.e., not for free).
Study NCT00862277 — intervention group
Intervention type: BIOLOGICAL
Intervention: Menomune®
Description: 0.5 mL, Intramuscular (from a previous study)
Study NCT01964560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use
Study NCT01964560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use
Study NCT03690999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product
Study NCT03690999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Description: Prebiotic supplement
Study NCT02935543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART 19
Description: CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10\^7 CART19 cells, Day 2, 30% fraction: 3x10\^7-1.5x10\^8 CART19 cells, Day 3, 60% fraction: 6x10\^7-3x10\^8 CART19 cells
Study NCT01843478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Collected HPV Test
Description: The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
Study NCT01843478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study NCT03705624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Community Case Management (CCM)
Description: Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
Study NCT03210077 — intervention group
Intervention type: DEVICE
Intervention: Monitoring
Description: Monitoring
Study NCT04730323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded.
Study NCT04730323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded.
Study NCT04427592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
Study NCT03705624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Screening and Treatment (MSAT)
Description: Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
Study NCT03639532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: COC THA
Description: standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
Study NCT03639532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COP THA
Description: standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
Study NCT03845465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect + Education
Description: Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
Study NCT03845465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
Study NCT03845465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
Study NCT00731432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transmucosal Herbal Periodontal Patch (THPP)
Description: Patch applied to oral gingiva
Study NCT04427592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure of uterine wall defect
Description: uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
Study NCT00693381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study NCT00693381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT02919956 — intervention group
Intervention type: OTHER
Intervention: Neurodevelopmental Testing
Description: Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
Study NCT04483596 — intervention group
Intervention type: DRUG
Intervention: melatonin effect on the Abbreviated Mental Test
Description: Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1
Study NCT02614898 — intervention group
Intervention type: OTHER
Intervention: Eculizumab
Description: This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.
Study NCT02075385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre, during and pos-treatment swallowing exercises
Description: Speech pathology therapy
Study NCT04429971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP screening program
Description: ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
Study NCT01664650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein
Study NCT01664650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00606658 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Shirodhara Oil Treatment
Description: Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
Study NCT01325740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STX107
Description: STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
Study NCT01325740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STX107
Description: STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
Study NCT03544216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal Contact Lens
Description: The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
Study NCT03544216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Vision Contact Lens
Description: The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
Study NCT04600635 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
Study NCT02169323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step-down
Description: Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
Study NCT02127216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOSES
Description: MOSES is an integrated system between a patient, peer patients, and healthcare providers.
Study NCT01023113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PASCAL laser
Description: PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
Study NCT01023113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laser
Description: PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
Study NCT01698736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Membrane filtration
Description: Membrane filtration (Polysulfone)
Study NCT01698736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Semiselective IA
Description: Semiselective immunoadsorption (GAM peptide adsorber)
Study NCT01698736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semiselective IA
Description: Semiselective immunoadsorption (GAM peptide adsorber)
Study NCT01049464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
Study NCT01049464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
Study NCT02784236 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: telemedicine
Description: The study population corresponds to patients> 18 and \<65 years with DM1 of> 1 year of evolution, and treated with MDI HbA1c> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
Study NCT00673660 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Compliance
Description: Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
Study NCT05762016 — intervention group
Intervention type: PROCEDURE
Intervention: Bedside Mini-Incision and Self-Express (MISE)
Description: To perform bedside mini incision and encourage patients to self express the pus following the intervention
Study NCT03097692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemic preconditioning
Description: ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
Study NCT03097692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacologic preconditionig
Description: Pharmacologic preconditionig will be attained by sevoflurane anesthesia
Study NCT04429971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PrEP screening program
Description: ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
Study NCT04429971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP starter pack
Description: emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil
Study NCT00292370 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Open Label (OL) Paroxetine
Description: Open-label Paroxetine
Study NCT00292370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open Label (OL) Paroxetine
Description: Open-label Paroxetine
Study NCT00292370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label (OL) Paroxetine
Description: Open-label Paroxetine
Study NCT00292370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo taken with OL paroxetine
Study NCT00292370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Double-blind quetiapine taken with OL paroxetine
Study NCT01435980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass
Description: basal treatment and Gastric Bypass
Study NCT01435980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: basal treatment and Exenatide
Study NCT01123525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: 1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
Study NCT01123525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: 1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
Study NCT04209803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil 5% topically and oral NAC 600 mg
Description: Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
Study NCT02301429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model 20105
Description: implant and follow-up of study device
Study NCT02238327 — intervention group
Intervention type: PROCEDURE
Intervention: blood draw
Description: Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
Study NCT03785340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
Study NCT03785340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
Study NCT01374451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
Study NCT01374451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
Study NCT02238327 — intervention group
Intervention type: PROCEDURE
Intervention: questionnaires
Description: The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
Study NCT01545349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103 (LGG)
Description: Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days